Jennison Associates
NGM

Jennison Associates’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Jennison Associates’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-122,430
Closed -$1.6M – 639
2022
Q3 		$1.6M Buy
+122,430
New +$1.85M ﹤0.01% 468

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates's NGM Position: Q4 2022 in Review

Jennison Associates sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2022, closing a stake of 122,430 shares — an estimated $1.6M sold.

Jennison Associates first reported a position in NGM in Q3 2022 and held it in 1 quarter. The position peaked at $1.6M in Q3 2022. 125 funds tracked by Wall St. Rank hold NGM as of Q4 2022.

  • Jennison Associates reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Jennison Associates sold 122,430 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $1.6M.
  • Jennison Associates first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Jennison Associates's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.6M in Q3 2022.
  • 125 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Jennison Associates's 13F filing for Q4 2022, filed 9 Feb 2023.